A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Merck KGaA drops two cancer trials on assets from SpringWorks deal
Parasitology Market Is Going to Boom | Thermo Fisher Scientific • Merck KGaA • Abbott Laboratories - openPR.com
Parasitology Market Is Going to Boom | Thermo Fisher Scientific • Merck KGaA • Abbott Laboratories - openPR.com
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo
Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
Bacterial Protein Market Is Going to Boom |• Thermo Fisher Scientific • Merck KGaA - openPR.com
Bacterial Protein Market Is Going to Boom |• Thermo Fisher Scientific • Merck KGaA - openPR.com
Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA
Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page